Full Breakdown
Curaleaf Launches Unsolicited $4-Per-Share Takeover Offer for Aurora Cannabis
8/12/2026, 1:55:04 AM
Core Offer and Terms
Curaleaf Holdings Inc. announced an unsolicited proposal to acquire all Aurora Cannabis Inc. shares at US $4.00 per Aurora share (0.3463 Curaleaf subordinate voting shares + US $0.75 cash). The offer is a 45 % premium to Aurora’s 30-day VWAP of US $2.75 and 110 % premium when cash is excluded. Curaleaf noted the consideration could rise to a US $5.00 cap if its own share price increases, lifting the premium to 82 % (or 197 % excluding cash).
Timeline of Negotiations
- June 23, 2026 – Curaleaf’s chairman and CEO Boris Jordan sent a formal letter of intent.
- July 7, 2026 – Follow-up letter detailed the financial terms.
- July 24, 2026 – Aurora’s lead independent director replied, noting focus on its short-to-medium-term plan while keeping dialogue open.
- December 18, 2025 – Aurora’s share price had previously traded above the US $5.00 cap now referenced.
Strategic Rationale and Financial Outlook
Curaleaf argues that merging Aurora’s EU-GMP cultivation and manufacturing capacity with its processing, distribution, and retail footprint would create a global cannabis platform in 17 countries. The combined entity would gain expanded U.S. market access, which Curaleaf describes as experiencing “regulatory tailwinds.” Curaleaf projects annual cost synergies of at least US $40 million after closing.
Official Statements & Responses
- Curaleaf’s CEO Boris Jordan expressed disappointment with Aurora’s board and said the proposal will now be presented directly to shareholders.
- Aurora confirmed receipt of the letters and said its board has formed a special committee of independent directors to evaluate the proposal. Aurora emphasized it will continue its strategic plan, including recent acquisitions such as Safari Flower Company, and that shareholders do not need to take any action at this time.
Data & Statistics
- Combined trailing-12-month revenue: reported as US $1.5 billion by some sources and US $5 billion by others.
- Proposed premium: 45 % to the 30-day VWAP; 110 % when cash is stripped out.
- Cost-synergy estimate: minimum US $40 million annually.
- Share-price reaction: Aurora’s TSX-listed shares rose roughly 13.6 % to C$4.58, U.S.–listed shares climbed about 14.8 % to US $3.32; Curaleaf’s shares increased around 1.2 %.
Conflicting Reports & Gaps
Sources differ on total revenue generated by the two companies over the past twelve months: some cite US $1.5 billion, others claim US $5 billion. Clarification from the companies’ financial disclosures is needed.
Verbatim Quotes
- “We believe this combination represents a win-win for Curaleaf and Aurora shareholders,” — Boris Jordan
- “We were very disappointed that the board refused to meaningfully engage,” — Boris Jordan
- “We believe [Aurora's] market leadership in medical cannabis, high-quality product portfolio, strong balance sheet, and proven ability to navigate complex international regulatory requirements position the company to create significantly greater value over time.” — Boris Jordan
